within Pharmacolibrary.Drugs.D_Dermatologicals.D05B_AntipsoriaticsForSystemicUse.D05BB02_Acitretin;

model Acitretin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.6,
    Cl = 3.422222222222222e-06,
    adminDuration = 600,
    adminMass = 50 / 1000000,
    adminCount = 1,
    Vd = 0.019,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.00036666666666666667,
    Tlag = 2400,
    Vdp = 0.0027,
    k12 = 0.00010305555555555556,
    k21 = 0.00010305555555555556);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Acitretin</td></tr><tr><td>ATC code:</td><td>D05BB02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>50</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>19.0</td><td>L</td></tr>
    <tr><td>clearance:</td><td>176</td><td>mL/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Acitretin is an oral retinoid primarily used for the treatment of severe psoriasis and other disorders of keratinization. It is a second-generation, synthetic analog of vitamin A. Acitretin has been approved for clinical use in several countries, but is contraindicated in women of childbearing age due to its high teratogenic potential.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral administration of acitretin 50 mg.</p><h4>References</h4><ol><li><p>Balato, N, et al., &amp; Scarpa, R (2014). Managing moderate-to-severe psoriasis in the elderly. <i>Drugs &amp; aging</i> 31(4) 233–238. DOI:<a href=\"https://doi.org/10.1007/s40266-014-0156-6\">10.1007/s40266-014-0156-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24554398/\">https://pubmed.ncbi.nlm.nih.gov/24554398</a></p></li><li><p>Geiger, JM, et al., &amp; Saurat, JH (1994). Teratogenic risk with etretinate and acitretin treatment. <i>Dermatology (Basel, Switzerland)</i> 189(2) 109–116. DOI:<a href=\"https://doi.org/10.1159/000246811\">10.1159/000246811</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8075435/\">https://pubmed.ncbi.nlm.nih.gov/8075435</a></p></li><li><p>Park, HD, et al., &amp; Lee, SY (2009). A fully validated HPLC method for the simultaneous determination of acitretin and etretinate in plasma and its application to a pharmacokinetic study in healthy Korean subjects. <i>International journal of clinical pharmacology and therapeutics</i> 47(7) 476–482. DOI:<a href=\"https://doi.org/10.5414/cpp47476\">10.5414/cpp47476</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19640355/\">https://pubmed.ncbi.nlm.nih.gov/19640355</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.D.D05BB02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Acitretin;
